Paper628005
Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
Zee-Cheng RK and 1 other. J Med Chem, 1978. Cited by 249 papers, by iCite.
Cite this record
ConductScience Library. Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones. Papers, record 628005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/628005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anthraquinones | Major topic |
| Leukemia, Experimental | Major topic |
| Animals | |
| Antineoplastic Agents | |
| Melanoma | |
| Mice | |
| Neoplasms, Experimental | |
| Structure-Activity Relationship |
Source PubMed
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 249 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37821106 | In vitro reconstitution of SARS-CoV-2 Nsp1-induced mRNA cleavage reveals the key roles of the N-terminal domain of Nsp1 and the RRM domain of eIF3g. | Genes Dev | 2023 | https://conductscience.org/library/papers/37821106 | PubMed |
| 33562300 | Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33562300 | PubMed |
| 32975138 | DNA topoisomerases as molecular targets for anticancer drugs. | J Enzyme Inhib Med Chem | 2020 | https://conductscience.org/library/papers/32975138 | PubMed |
| 30005668 | Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers. | J Nanobiotechnology | 2018 | https://conductscience.org/library/papers/30005668 | PubMed |
| 28820965 | Systematic Identification of MCU Modulators by Orthogonal Interspecies Chemical Screening. | Mol Cell | 2017 | https://conductscience.org/library/papers/28820965 | PubMed |
| 28523107 | Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer. | ACS Med Chem Lett | 2017 | https://conductscience.org/library/papers/28523107 | PubMed |
| 21528870 | Asymmetric enzymatic glycosylation of mitoxantrone. | Org Lett | 2011 | https://conductscience.org/library/papers/21528870 | PubMed |
| 20135310 | Chemotherapeutic potential of 9-phenyl acridine: biophysical studies on its binding to DNA. | Eur Biophys J | 2010 | https://conductscience.org/library/papers/20135310 | PubMed |
| 17483512 | Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. | Nucleic Acids Res | 2007 | https://conductscience.org/library/papers/17483512 | PubMed |
| 17074670 | Anticancer drug discovery and pharmaceutical chemistry: a history. | Clin Transl Oncol | 2006 | https://conductscience.org/library/papers/17074670 | PubMed |
| 8918789 | Site-specific and photo-induced alkylation of DNA by a dimethylanthraquinone-oligodeoxynucleotide conjugate. | Nucleic Acids Res | 1996 | https://conductscience.org/library/papers/8918789 | PubMed |
| 8262731 | Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group. | Invest New Drugs | 1993 | https://conductscience.org/library/papers/8262731 | PubMed |
| 8190623 | DNA sequence specificity of mitoxantrone. | Nucleic Acids Res | 1994 | https://conductscience.org/library/papers/8190623 | PubMed |
| 7460190 | Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7460190 | PubMed |
| 7196864 | The immunoinhibitory and immunostimulatory effects of hydroxyanthra- and hydroxynaphthoquinone derivatives. | Folia Microbiol (Praha) | 1981 | https://conductscience.org/library/papers/7196864 | PubMed |
| 7105379 | Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105379 | PubMed |
| 7094196 | Pharmacology of mitoxantrone in cancer patients. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7094196 | PubMed |
| 6690066 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6690066 | PubMed |
| 6687221 | Correlation of the structure of amino-substituted anthraquinones to cytotoxicity in cultured Chinese hamster cells. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6687221 | PubMed |
| 6678863 | Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678863 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/628005
GET https://conductscience.org/api/papers/v1/628005/cited_by?page=2